by nobilistx | Feb 18, 2018 | Uncategorized |
Drs. Meloni and Bogin were invited to discuss Nobilis Therapeutics’ PTSD clinical development program in front of the US Congress. As treatment for PTSD remains a tremendous unmet need, there is a significant interest on the part of the Congress, VA, DoD and...
by nobilistx | Jan 31, 2018 | Uncategorized |
In early April Nobilis Therapeutics will present the results of its clinical trial of NBTX-001 in patients with Panic Disorder at the annual conference of Anxiety and Depression Association of America (ADAA). This is the first documented study of xenon-based...
by nobilistx | Dec 20, 2017 | Uncategorized |
Nobilis Therapeutics leadership will be attending J.P.Morgan’s 36th Annual Healthcare Conference that will take place in San Francisco on January 8-11. If you are interested in setting up a f2f meeting with our team, please send us an...
by nobilistx | Oct 26, 2017 | Uncategorized |
Mr. Bogatyrenko is a proven pharmaceutical executive, having served in multiple operational and consulting roles in the life sciences industry. Most recently he was a SVP, Business Development at Paratek Pharmaceuticals in Boston where he developed global and regional...
by nobilistx | Oct 5, 2017 | Uncategorized |
A consensus statement of the PTSD Psychopharmacology Working Group has clearly identified treatment of PTSD, a disease without any effective pharmacotherapy, as a severe unmet medical need. The group has analyzed scientific data on potential efficacy of a multitude of...
